Trial Profile

Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Zirconium-89 cetuximab (Primary) ; Panitumumab
Indications Adenocarcinoma; Colorectal cancer; Liver metastases
Focus Pharmacokinetics; Therapeutic Use
Acronyms IMPACT-CRC

Most Recent Events

04 Jun 2024 Results assessing the predictive performance of early evaluation of metabolic rate with [18F]FDG PET/CT and baseline and after 1 intravenous anti-EGFR mAb administration to distinguish patients with and without clinical benefit, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
07 Mar 2021 Status changed from recruiting to discontinued.
05 Oct 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com